利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

116 条记录 (耗时 0.055 秒)

    Method of forming an image by silver salt diffusion transfer
    1.
    发明授权
    Method of forming an image by silver salt diffusion transfer 失效
    通过银盐扩散转移形成图像的方法

    公开(公告)号：US5073473A

    公开(公告)日：1991-12-17

    申请号：US467292

    申请日：1990-01-16

    申请人： Keizo Koya ,  Yoshio Idota

    发明人： Keizo Koya ,  Yoshio Idota

    IPC分类号： G03C8/06

    CPC分类号： G03C8/06 ,  Y10S430/156

    摘要： A method for forming an image by silver salt diffusion transfer is described, comprises processing an imagewise exposed photosensitive element provided with a layer of photosensitive silver halide emulsion on a support, and an image-receiving element provided with an image-receiving layer containing a silver-precipitating agent on a support, with an alkali processing composition in the presence of a silver halide solvent, to convert at least part of the unexposed silver halide in the emulsion layer into a transferable silver complex salt, to transfer at least part of said complex salt into the image-receiving layer, and to form an image in the image-receiving layer; the processing being carried out in the presence of at least one compound as described.

    摘要翻译： 描述了通过银盐扩散转移形成图像的方法，包括在载体上处理具有感光卤化银乳剂层的图像曝光感光元件，以及设置有包含银的图像接收层的图像接收元件 在载体上，在卤化银溶剂存在下用碱处理组合物将所述乳液层中的至少部分未曝光的卤化银转化为可转移的银络合盐，以将至少部分所述复合物 盐进入图像接收层，并在图像接收层中形成图像; 该处理在至少一种所述化合物存在下进行。

    Combination with bis(thiohydrazide amides) for treating cancer
    6.
    发明授权
    Combination with bis(thiohydrazide amides) for treating cancer 有权
    与双（硫代酰肼酰胺）结合治疗癌症

    公开(公告)号：US07939564B2

    公开(公告)日：2011-05-10

    申请号：US11897538

    申请日：2007-08-30

    申请人： Keizo Koya

    发明人： Keizo Koya

    IPC分类号： A61K31/16

    CPC分类号： A61K31/16 ,  A61K31/165 ,  A61K31/337 ,  A61K41/0052 ,  A61K45/06 ,  A61K2300/00

    摘要： Disclosed herein are methods of treating a proliferative disease, such as cancer, with bis(thio-hydrazide amides) or a tautomer, pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, in combination with hyperthermia treatment. Also disclosed are methods of treating a proliferative disease, such as cancer, with bis(thio-hydrazide amides) or a tautomer, pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, in combination with radiotherapy.

    摘要翻译： 本文公开了与双热（硫代酰肼）酰胺或其互变异构体，药学上可接受的盐，溶剂合物，包合物或前药，与热疗治疗结合治疗增殖性疾病如癌症的方法。 还公开了与放射治疗组合的双（硫代 - 酰肼）酰胺或其互变异构体，药学上可接受的盐，溶剂合物，包合物或前药治疗增殖性疾病如癌症的方法。

    Paclitaxel enhancer compound
    9.
    发明授权
    Paclitaxel enhancer compound 失效
    紫杉醇增强剂化合物

    公开(公告)号：US07750042B2

    公开(公告)日：2010-07-06

    申请号：US12077729

    申请日：2008-03-20

    申请人： Keizo Koya ,  Lijun Sun ,  Shoujun Chen ,  Noriaki Tatsuta ,  Yaming Wu ,  Mitsunori Ono ,  Zhi-Qiang Xia

    发明人： Keizo Koya ,  Lijun Sun ,  Shoujun Chen ,  Noriaki Tatsuta ,  Yaming Wu ,  Mitsunori Ono ,  Zhi-Qiang Xia

    IPC分类号： A61K31/335 ,  A61K31/20 ,  C07C327/38 ,  C07C243/18

    CPC分类号： C07D307/68 ,  A45D2008/006 ,  A61K31/337 ,  A61K31/505 ,  A61K31/53 ,  A61K31/5377 ,  A61K47/58 ,  C07C327/56 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07D209/42 ,  C07D209/44 ,  C07D213/83 ,  C07D261/18 ,  C07D333/38 ,  C07D333/68

    摘要： One embodiment of the present invention is a compound represented by the Structural Formula (I): Y is a covalent bond of a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C═Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or —C(R7R8)—. R1 is an aliphatic group, a substituted aliphatic group, a non-aromatic heterocyclic group, or a substituted non-aromatic heterocyclic group, R2-R4 are independently —H, an aliphatic group, a substituted aliphatic group, a non-aromatic heterocyclic group, a substituted non-aromatic heterocyclic group, an aryl group or a substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. R5-R6 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R7 and R8 are each independently —H, an aliphatic or substituted aliphatic group, or R7 is —H and R8 is a substituted or unsubstituted aryl group, or, R7 and R8, taken together, are a C2-C6 substituted or unsubstituted alkylene group. Z is ═O or ═S. Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent.

    摘要翻译： 本发明的一个实施方案是由结构式（I）表示的化合物：Y是取代或未取代的直链烃基的共价键。 此外，Y与它所键合的两个> C = Z基团一起是取代或未取代的芳族基团。 优选Y为共价键或-C（R 7 R 8） - 。 R1是脂肪族基团，取代脂肪族基团，非芳族杂环基团或取代的非芳族杂环基团，R2-R4独立地是-H，脂肪族基团，取代的脂肪族基团，非芳香族杂环基 ，取代的非芳族杂环基，芳基或取代的芳基，或者R 1和R 3与它们所键合的碳原子和氮原子一起，和/或R 2和R 4与碳和氮原子一起 形成与芳环稠合的非芳族杂环。 R5-R6独立地是-H，脂族基团，取代的脂族基团，芳基或取代的芳基。 R 7和R 8各自独立地为-H，脂族或取代的脂族基团，或者R 7为-H且R 8为取代或未取代的芳基，或者R 7和R 8一起为C 2 -C 6取代或未取代的亚烷基 。 Z为═O或═S。 还公开了包含本发明化合物和药学上可接受的载体或稀释剂的药物组合物。